Industry Expert Sessions

Date Time (BST) Symposium Details
Sunday 25th April 18:00 - 18:45

Novartis - Diagnosis, testing and management of FLT3+ AML patients

Sunday 25th April 18:00 - 18:45

Novartis - Managing myelofibrosis (MF) patients with confidence

Monday 26th April 07:30 - 08:15

medac Pharma - Advances in conditioning regimens for allogeneic stem cell transplantation.

Dr Amit Patel – Consultant in Cellular Therapies and Transplantation, The Christie NHS Foundation Trust

This is a medac Pharma sponsored session, discussing the application of innovative conditioning regimens for allogeneic stem cell transplantation.

There will be presentations of key data from clinical trials, including exploration of the efficacy of a Treosulfan as an alternative alkylating agent to Busulfan within conditioning regimens. Following publication of the large pivotal, phase III, randomised trial (Beelen et al., 2019), a NICE recommendation was made in 2020. NICE recommended use of a Treosulfan (Trecondi®) based conditioning regimen in people with malignant diseases, making it the only NICE recommended conditioning regimen within allo-HSCT.

This session will include Dr Amit Patel’s personal experience of using a Treosulfan based conditioning regimen. This will provide valuable insights of best practice in transplantation for using and adopting such novel conditioning regimens in the future.

Following the presentations, there will be a Q&A session during which audience members can ask any questions.

Monday 26th April 12:00 - 12:45 Novartis Roundtable - An interactive discussion exploring challenges and opportunities regards how to optimise access to CAR-T for Paediatric and Teenage & Young Adult patients with Acute Lymphoblastic Leukaemia.
Tuesday 27th April 12:15 - 13:00 Beigene - Expert Discussion: Management of Waldenstrom Macroglobulineamia in 2021
Tuesday 27th April 12:00 - 12:45 Janssen - Expert Talk - Practicalities and Clinical Significance of MRD Testing in Myeloma

Dr Dean Smith (Nottingham University Hospitals NHS Trust)
Dr Ruth de Tute (Leeds Teaching Hospitals NHS Trust).
Tuesday 27th April 18:15 - 19:00

AstraZeneca - Roundtable Discussion: Managing CLL Post the Pandemic

In this AstraZeneca organised meeting, expert faculty members will discuss the current environment in chronic lymphocytic leukaemia (CLL) management and explore the opportunities created for patients in an era of targeted oral therapies. Our panel will be providing their views on the impact and future implications of COVID-19 on CLL treatment, including key considerations for optimal use of oral therapies and how we can adapt to a ‘new normal’.

This 45-minute meeting will have an open format to facilitate discussion and questions from the audience. We look forward to your participation in this meeting discussing important aspects of CLL treatment and patient management.


Professor George Follows (Chair),
Consultant Haematologist and Clinical Lead for Lymphoma and CLL, Cambridge University Hospitals NHS Foundation Trust

Professor Anna Schuh,
Director of Molecular Diagnostics, University of Oxford and Honorary Consultant Haematologist

Dr Sunil Iyengar,
Consultant Haematologist, The Royal Marsden NHS Foundation Trust and Honorary Lecturer at the Institute of Cancer Research

Orla Stewart,
Lead Nurse in Haematology, King’s College Hospital NHS Foundation Trust

Intended for UK Healthcare Professionals Only. This is an AstraZeneca promotional meeting.

Date of preparation: February 2021

Job number: GB-27071

Wednesday 28th April 12:00 - 12:45

Novartis - The ITP treatment landscape: current unmet needs

Wednesday 28th April 12:00 - 12:45

AbbVie - Meet The Expert: Reviewing CLL patient cases